insights_auto
Bakit tumaas ang KYNB 2.52%?
Tingnan ang Higit pang Detalyechevron_right
KYNB:NASDAQ
Kyntra Bio Inc
$6.11
arrow_upward
+2.52%(+0.15) 1D
Okt 9, 4:00:00 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa KYNB...
Buksan
$6.08
Mataas
$6.26
Mababa
$6.08
Mkt. cap
24.74M
Avg. na dami
25.82K
Dami
0.00
P/E ratio
0.13
Mataas nang 52-wk
$9.70
Mababa nang 52-wk
$5.62
EPS
$45.30
Beta
1.05
Mga natitirang share
4.05M
Bilang ng mga empleyado
34
Buksan
$6.08
Mataas
$6.26
Mababa
$6.08
Mkt. cap
24.74M
Avg. na dami
25.82K
Dami
0.00
P/E ratio
0.13
Mataas nang 52-wk
$9.70
Mababa nang 52-wk
$5.62
EPS
$45.30
Beta
1.05
Mga natitirang share
4.05M
Bilang ng mga empleyado
34
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Bloomberg.com
·
19 minuto ang nakalipas
Oil Rises on Mideast Attacks, Dollar Edges Higher: Markets Wrap
Yardeni QuickTakes
·
6 oras ang nakalipas
S&P 500 SECTORS CALL: More Green On The Screen
Investor's Business Daily
·
1 buwan ang nakalipas
Dow Jones Futures: Techs Set To Run? Nvidia, CrowdStrike, Okta, Salesforce Jump On Earnings
Reuters
·
1 linggo ang nakalipas
Panmure Liberum forecasts S&P 500 falling to 5,000, warns bull run nearing end
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Tungkol sa Kyntra Bio Inc
CEO-
Mga Empleyado34
ItinatagEne 1, 1993
HeadquartersSan Francisco, California, Estados Unidos
Sektor-
Websitekyntrabio.com